Search the Newsreel

Piper Sandler raises First Tracks stock price target on pipeline progress

Wedbush Issues Positive Forecast for First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Price

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

First Tracks Biotherapeutics (TRAX) Earnings Date and Reports 2026 $TRAX

First Tracks Biotherapeutics 2Q 2026: Net loss $(33.4M), EPS $(0.95) — 10-Q Summary

First Tracks Biotherapeutics reported a net loss of $(33.4M) and diluted EPS of $(0.95) for Q2 2026, an improvement compared to the previous year. The company's cash and cash equivalents stood at $168M as of June 30, 2026, with management indicating a funding runway …

First Tracks Biotherapeutics (TRAX) details $83.9M loss and $168M cash after spin-off

First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates

UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65

UBS has initiated coverage on First Tracks Biotherapeutics (TRAX.US) with a "Buy" rating. The investment bank also announced a target price of $65 for the company's stock. This initiation suggests a positive outlook from UBS on the future performance of First Tracks Biotherapeutics.

First Tracks Biotherapeutics (TRAX) awards 60,492 PSUs to CMO

First Tracks Biotherapeutics (TRAX) has granted 60,492 performance stock units (PSUs) to its Chief Medical Officer, Paul F. Lizzul, following the achievement of performance criteria. This grant increases his total PSU holdings to 77,159. The PSUs will vest and settle over two years, with …

First Tracks Biotherapeutics (TRAX) awards 60,492 performance stock units

First Tracks Biotherapeutics (TRAX) has awarded Chief Business Officer Benjamin Stone 60,492 performance-based restricted stock units (PSUs). These PSUs were earned upon the achievement of specific performance criteria certified on August 2, 2026, with each unit representing one share of common stock. The units …

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

First Tracks Biotherapeutics Eyes Late-2026 Celiac Data, Wedbush Analyst Raises Price Target To $60

First Tracks Biotherapeutics (TRAX) is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. The company anticipates key milestones in its immunology pipeline, specifically for ANB033 which is currently undergoing Phase 1b trials for celiac disease and eosinophilic esophagitis. Wedbush has raised its …

First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo

First Tracks Biotherapeutics Ord Shs

TRAX Stock Volatile As Traders Focus On Cash And Momentum

First Tracks Biotherapeutics Inc. (TRAX) stock has seen significant volatility, nearly doubling from early-month lows due to positive clinical trial news, despite reporting negative earnings and cash flow. The company maintains a strong balance sheet with substantial cash reserves relative to liabilities, allowing for …

First Tracks Biotherapeutics Inc. (TRAX) Stock Price | Live Quotes & Charts | NASDAQ

TRAX SEC Filings - First Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms

First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long (TRAX)

First Tracks Biotherapeutics (TRAX) 10K Form and Latest SEC Filings 2026

First Tracks Biotherapeutics Inc (TRAX) Stock Price, Quote, News & History

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

First Tracks targets $180M cash at launch after $145M financing